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Background: Surgery is the primary treatment for patients
with stage I, II, or IIIA non–small-cell lung cancer (NSCLC).
However, long-term survival of NSCLC patients after sur-
gery alone is largely unsatisfactory, and the role of adjuvant
chemotherapy in patient survival has not yet been estab-
lished. Methods: Between January 1994 and January 1999,
1209 patients with stage I, II, or IIIA NSCLC were randomly
assigned to receive mitomycin C (8 mg/m2 on day 1), vinde-
sine (3 mg/m2 on days 1 and 8), and cisplatin (100 mg/m2 on
day 1) every 3 weeks for three cycles (MVP group; n = 606)
or no treatment (control group; n = 603) after complete
resection. Randomization was stratified by investigational
center, tumor size, lymph-node involvement, and the inten-
tion to perform radiotherapy. The primary endpoint was
overall survival and secondary endpoints were progression-
free survival and toxicity associated with adjuvant treat-
ment. Survival curves were analyzed using the log-rank test.
All statistical tests were two-sided. Results: After a median
follow-up time of 64.5 months, there was no statistically sig-
nificant difference between the two patient groups in overall
survival (hazard ratio = 0.96, 95% confidence interval = 0.81
to 1.13; P = .589) or progression-free survival (hazard ratio
= 0.89, 95% confidence interval = 0.76 to 1.03; P = .128).
Only 69% of patients received the three planned cycles of
MVP. Grades 3 and 4 neutropenia occurred in 16% and
12%, respectively, of patients in the MVP arm. Radio-
therapy was completed by 65% of patients in the MVP arm
and by 82% of patients in the control group. In the multi-
variable analysis, only disease stage and sex were associated
with survival. Conclusion: This randomized trial failed to
prospectively confirm a statistically significant role for ad-
juvant chemotherapy in completely resected NSCLC. Given
the poor compliance with the MVP regimen used in this
study, future studies should explore more effective treat-
ments. [J Natl Cancer Inst 2003;95:1453–61]
Although radical surgery is the primary treatment for early
non–small-cell lung cancer (NSCLC), the long-term survival of
patients who undergo surgery alone is largely disappointing,
with estimated 5-year survival rates ranging from 67% for those
with pathologic stage IA disease to 39% for those with patho-
logic stage IIB disease (1). Among patients who undergo surgery
alone, relapses occur more commonly at distant sites (2–5), and
the efficacy of adjuvant treatments remains unproven [reviewed
in (6)].
In 1995, a meta-analysis reviewed eight cisplatin-based ad-
juvant chemotherapy trials that enrolled 1394 NSCLC patients
and reported that such therapy was associated with a 13% re-
duction of the risk of death. However, that risk reduction was of
borderline statistical significance (7). In the early 1990s, results
of a randomized clinical trial in patients with advanced NSCLC
demonstrated that two different chemotherapy triplet combina-
tions—mitomycin C, ifosfamide, and cisplatin and mitomycin C,
vindesine, and cisplatin (MVP)—were superior to the doublet
combination of cisplatin and etoposide in terms of overall re-
sponse rate and survival (8). Of the three chemotherapies exam-
ined, MVP yielded the best median survival time, an incidence
of grades 3 and 4 toxicities comparable to that associated with
the doublet combination of cisplatin and etoposide, and a better
therapeutic ratio than mitomycin C, ifosfamide, and cisplatin (8).
To investigate the potential benefits of adjuvant chemotherapy
for survival, we designed Adjuvant Lung Project Italy (ALPI), a
randomized trial to test the MVP regimen in patients with radi-
cally resected stages I–II and IIIA NSCLC.
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PATIENTS AND METHODS
Study Design and Treatment Schedules
From January 1994 through January 1999, 66 Italian centers
participated in this study; beginning in April 1995, five Euro-
pean centers located outside Italy that were affiliated with the
European Organisation for Research and Treatment of Cancer
(EORTC)–Lung Cancer Cooperative Group (LCCG) joined the
study. Data monitoring and quality-control procedures were set
in place to ensure the quality of the information collected by the
participating centers. These procedures included random site
visits and source validation procedures. An independent data
monitoring committee was set up to check the progress of the
trial. One interim analysis was planned and performed on data
collected as of June 1998 and submitted to the independent data
monitoring committee of the study. It was then decided to con-
tinue the follow-up of the patients until reaching the planned
number of events.
After surgery, patients who fulfilled the eligibility criteria
were randomly assigned to receive the MVP regimen (mitomy-
cin C at 8 mg/m2 on day 1, vindesine at 3 mg/m2 on days 1 and
8, and cisplatin at 100 mg/m2 on day 1 every 3 weeks for three
cycles) or no chemotherapy. Randomization was performed cen-
trally by the Laboratory of Clinical Cancer Research at the
Mario Negri Institute (Milan, Italy) and by the EORTC Data
Center (Brussels, Belgium). Stratification included tumor size
and lymph-node involvement, which were defined according to
the tumor–node–metastasis staging system (9), investigational
center, and intended radiotherapy. All patients were randomly
assigned to a treatment group within 42 days after surgery. Writ-
ten informed consent was obtained from each patient before
study entry. The study was approved by the local ethical review
boards and the protocol review committee of the EORTC; we
also followed the recommendations of the Declaration of Hel-
sinki for biomedical research involving human subjects.
Dose adjustments within a treatment cycle were based on
patients’ absolute neutrophil and platelet counts, which were
measured on day 8 of each cycle of therapy, and on the assess-
ment of non-hematologic toxicities. Patients who experienced
progressive disease (defined as recurrence or relapse of radio-
logically or clinically detectable neoplastic disease) or unaccept-
able toxicity (defined as grade 4 hematological toxicity persist-
ing at day 1 of the subsequent courses of chemotherapy or any
grade 4 nonhematological toxicity occurring at any time during
the chemotherapy treatment), or who did not receive chemo-
therapy for 6 weeks from the time of the last treatment, were
discontinued from the study. The second and the third cycles of
chemotherapy were administered every 3 weeks only to patients
who had fully recovered from toxicities associated with the pre-
vious cycle of therapy; otherwise, chemotherapy was delayed for
1 week and, for patients with any persisting grade 2 toxicity, a
25% dose reduction was planned on day 28. For patients with
any higher grade toxicities, the chemotherapy cycle was further
delayed by 1 week. Toxicity was graded according to World
Health Organization criteria (10).
Patients received adjuvant radiotherapy according to the
policy of the individual participating center. The treatment
policy for adjuvant radiotherapy was decided before the first
patient from each center was enrolled into the study and was
applied, according to each stage of the disease, in all patients
from that specific center; for patients in the MVP arm, radio-
therapy was initiated 3–5 weeks after the last MVP treatment
and for patients in the control arm, radiotherapy was initiated
4–6 weeks after radical surgery. In both study arms, the total
radiotherapy dose was 50–54 Gy (2 Gy/day, 5 days/week) over
5–6 weeks. Radiotherapy was administered to the clinical target
volume through two or three antero-posterior, postero-anterior,
lateral, or oblique fields. In cases of documented extracapsular
invasion of any lymph node, an additional dose of 6 Gy was
specifically delivered to those involved areas. Acute toxicities
and late toxicity associated with radiotherapy were graded ac-
cording to Radiation Therapy Oncology Group criteria (11).
After patients were off the protocol therapy (chemotherapy
and/or radiotherapy), we assessed their disease status by moni-
toring them every 3 months for the first 2 years, then every 6
months during the third year, and annually thereafter. Monitor-
ing consisted of a clinical examination. Each patient received a
chest x-ray every 6 months for the first 2 years after completion
of chemotherapy and/or radiotherapy, and then once a year
thereafter. In 2002, patients who were still alive were flagged
with the National Death Registry to ensure the collection of
long-term mortality data. Median follow-up time was 64.5
months.
Eligibility and Exclusion Criteria
Patients who had undergone complete resection of pathologi-
cally documented stage I, II, or IIIA NSCLC by either lobec-
tomy or pneumonectomy were eligible for this study. Patients
who had more limited, albeit pathologically complete, resections
were also eligible for our study. We used the International Union
Against Cancer (UICC) and American Joint Committee on Can-
cer staging system (9) for lung cancer as a guide to stage pa-
tients. Lymph-node involvement was defined according to the
criteria of the American Thoracic Society (12). Surgical proce-
dures used for staging and treatment of mediastinal lymphatics
included complete dissection of mediastinal lymph nodes at lev-
els 4, 7, and 10 during right-sided thoracotomy and at levels 5
and/or 6 and 7 during left-sided thoracotomy or, alternatively, a
systematic sampling of representative lymph nodes at the speci-
fied levels.
Additional eligibility criteria included adequate bone marrow
reserves (i.e., white blood cell count, 3.5 × 109 cells/L; plate-
lets, 120 × 109 cells/L; hemoglobin, 10 g/L; and hematocrit,
30%), adequate liver and renal function (i.e., creatinine level
<1.5 times the upper normal limit), and a postoperative forced
expiratory volume of greater than 1.2 L in 1 second.
Prospective Evaluation of Molecular Markers
In selected participating centers, tumor tissue samples were
centrally collected and evaluated for the degree of positivity to
p53 and Ki67 immunostaining and for the presence or absence of
K-ras mutations at codon 12, the commonest site in lung cancer.
Formalin-fixed, paraffin-embedded specimens from surgically
removed tumors were incubated with antibodies to p53 (Ab-2;
Oncogene Sciences, Manhasset, NY) or to Ki67 (MIB-1; DAKO,
Glostrup, Denmark), and immunoreactivity was visualized as
previously described (13,14). We categorized tumors into four
grades according to the proportion of labeled neoplastic cells
they contained, as detailed in a previous study (14): grade 0 
0%–5% Ki67-positive cells or 0% p53-positive cells; grade 1
6%–10% Ki67-positive cells and 1%–10% p53-positive cells;
grade 2  >10%–25% Ki67-positive or p53-positive cells;
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grade 3  >25% Ki67-positive or p53-positive cells. These
cutoff points were selected a priori and were based on previ-
ously reported data (13,14).
Sections were cut from paraffin-embedded tumor samples
and collected in an Eppendorf tube. The DNA in the sections
was heat-denatured by using a rapid lysis technique (15) and was
used for amplification in vitro. Conditions for the polymerase
chain reaction (PCR) and the detection of point mutations for
codon 12 in exon 1 of K-ras using mutation-specific oligonu-
cleotides followed previously published procedures, and results
were categorized for the presence or absence of point mutations
at codon 12 (16).
Statistical Analysis
The primary endpoint was overall survival, which was de-
fined as the time from randomization to death from any cause.
Secondary endpoints were progression-free survival (defined as
the time from randomization to the earliest occurrence of relapse
or death from any cause) and toxicity associated with chemo-
therapy. The trial was designed to have an 80% power to detect
a 20% relative reduction in mortality (i.e., increasing 5-year
survival rate from 50% to 57%, corresponding to a hazard ratio
[HR] of 0.8) with a two-sided  of .05. We anticipated that 1300
patients would have to be recruited to the trial over 5 years to
provide the 535 events necessary to meet these specifications.
The study was closed prematurely after having enrolled 93% of
the planned sample size, because the accrual rate was low during
the last 6 months of the trial. However, we extended the follow-
up time to reach the originally planned number of events.
The data for all randomly assigned patients (including those
with protocol violations) were analyzed for overall survival on an
intent-to-treat basis using the log-rank test without adjustment for
prognostic factors. Additional analyses used a Cox proportional
hazards model adjusted for baseline characteristics after the verifi-
cation that proportional hazards assumptions were met. We used
the Kaplan–Meier estimate of overall or progression-free survival
in the control group at specific time points and the hazard ratio to
calculate absolute benefits at those time points according to the
formula: absolute benefit  e[HR − log(control survival)] − control survival,
where e is the base of natural logarithms. Although this approach
implicitly assumes proportional hazards, it is preferable to com-
paring differences between Kaplan–Meier curves at individual
time points. Differences in median progression-free and overall
survival times were calculated in a similar way, except that we
used the formula: difference in medians  (control group me-
dian/hazard ratio) – control group median. This approach as-
sumes approximately exponentially distributed survival curves.
We also developed a Cox proportional hazards model to assess
the effect of the molecular prognostic factors investigated. Pro-
visions for subgroup analyses were not included in the original
study design. We conducted a post hoc per-protocol analysis to
explore the relationship between progression-free and overall
survival and the amount of chemotherapy delivered.
RESULTS
Patient Characteristics
From January 1994 through January 1999, 1209 patients
(1086 from the Italian centers and 123 from EORTC–LCCG
centers) were enrolled in this study. We randomly assigned 606
patients to the MVP arm and 603 patients to the control arm
(Fig. 1). Thirteen patients were excluded from the analysis be-
cause of eligibility criteria violations (four in the MVP arm and
nine in the control arm; reasons for ineligibility are listed in Fig.
1). We excluded all 108 patients from one center (54 patients in
the MVP arm and 54 patients in the control arm) from the final
analysis because of serious concerns about data integrity. Thus,
this study reports on 548 patients in the MVP arm and 540
patients in the control arm (Fig. 1). However, we performed all
analyses of efficacy outcomes with and without the inclusion of
the 108 patients from that one center and found that the two sets
of results were not statistically significantly different.
Patient characteristics are reported in Table 1. Among the 470
patients who were scheduled to receive radiotherapy, 11 patients
(5%) in the MVP arm and nine patients (4%) in the control arm
had stage I NSCLC, 107 patients (45%) in the MVP arm and 112
patients (48%) in the control arm had stage II NSCLC, and 120
patients (50%) in the MVP arm and 111 patients (48%) in the
control arm had stage IIIA NSCLC.
Treatment Compliance
We collected full details about the MVP treatment received
by 508 patients (93% of those randomly assigned to the MVP
arm) and summaries of the MVP treatment received by the re-
maining patients. Of the 350 patients (69%) who completed the
MVP treatment, 177 did so with some dose adjustment or with
omission of part of the planned regimen (mainly the elimination
of vindesine administration on day 8). One hundred ten patients
(22%) stopped MVP treatment early because of toxicity (66
patients; 60%) or personal choice (44 patients; 40%). Forty-eight
patients (9%) never began MVP treatment, primarily because
they withdrew their consent to participate. The median doses of
cisplatin, mitomycin C, and vindesine actually delivered to pa-
tients were 96 mg/m2/cycle, 7.6 mg/m2/cycle, and 2.8 mg/m2/
cycle, respectively, corresponding to 96%, 95%, and 93%, re-
spectively, of the planned doses.
Fig. 1. Trial flow diagram for Adjuvant Lung Project Italy (ALPI), a randomized
trial to test the MVP regimen in patients with radically resected stages I–II and
IIIA non–small-cell lung cancer (NSCLC). MVP  mitomycin C (8 mg/m2 on
day 1), vindesine (3 mg/m2 on days 1 and 8), and cisplatin (100 mg/m2 on day
1) every 3 weeks for three cycles.
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We collected full details from selected centers about the ra-
diotherapy received by 331 patients (70% of those patients
scheduled to receive radiotherapy). Radiotherapy was completed
by 117 (65%) of the 179 evaluable patients in the MVP arm and
by 124 (82%) of the 152 evaluable patients in the control arm.
Forty-seven patients (26%) in the MVP arm and 16 patients
(11%) in the control arm did not complete the planned course of
radiotherapy because it was interrupted at an early stage.
Toxicity
In the MVP arm, grades 3 and 4 neutropenia occurred among
16% and 12% of the patients, respectively. Thrombocytopenia
was rarely reported (i.e., only 5% of patients had grade 3 or 4
thrombocytopenia); 20% of the patients had grade 2 anemia, but
only 2% of the patients had grade 3 anemia. In the MVP arm, the
incidence of nausea and vomiting was relatively low (grade 3
nausea and vomiting was reported for 13% of the patients; grade
4 nausea and vomiting was reported for 4% of the patients).
Other serious non-hematologic toxicities were infrequent (e.g.,
grade 3 neurotoxicity was reported for 3% of the patients; grade
2 ototoxicity was reported for 4% of the patients).
During sequential radiotherapy, the incidence of grade 3 or 4
hematologic toxicity was low (2% in the MVP arm, 3% in the
control arm), whereas grades 2 and 3 esophagitis were the most
commonly reported side effect (16% in the MVP arm and 15%
in the control arm). One patient in the control arm experienced
grade 4 esophagitis during radiotherapy. Grades 2 and 3 acute
pneumonitis were recorded for 10 patients (6%) in the MVP arm
and 13 patients (9%) in the control arm; grade 4 acute pneumo-
nitis was seen in two patients (1%) in the control arm.
Early deaths (i.e., deaths within 12 months after randomiza-
tion) were documented for 90 patients in the MVP arm and 69
patients in the control arm. The excess of early deaths among
patients in the MVP arm was attributable to cancer progression
(11 deaths) and to cardiopulmonary events (seven deaths). There
were 10 treatment-related deaths during the study (three in the
MVP arm and seven in the control arm); all except one (in the
control arm) occurred during the first year after randomization.
Among the patients who received radiotherapy, two patients
developed acute cardiac failure (one in the MVP arm and one in
the control arm), one patient in the MVP arm had radiation
pneumonitis, and seven patients developed respiratory failure
(one in the MVP arm and six in the control arm). No late toxicity
(i.e., at 3–6 months after the end of radiotherapy) was reported,
and no potential harmful interaction between previous adminis-
tration of mitomycin C and radiotherapy was documented.
Recurrence and Survival
The median duration of follow-up for all 1088 patients ana-
lyzed was 64.5 months (interquartile range  52.1–79.6
months). By May 2002, the number of observed deaths was 568
(52%; 279 in the MVP arm and 289 in the control arm). The
most common cause of death was progression of cancer, which
accounted for 71% of the deaths. Sixteen percent of deaths were
due to non-neoplastic causes, and 9% of deaths were from un-
known causes. Deaths due to a second primary cancer and treat-
ment-related deaths were documented in 11 patients (five pa-
tients in the MVP arm and six patients in the control arm) and 10
patients (three patients in the MVP arm and seven patients in the
control arm), respectively. As of May 2002, 456 patients (42%)
were still alive without evidence of disease, while the remaining
64 (6%) were alive with recurrent disease.
By May 2002, 437 patients had disease progression (199
patients in the MVP arm and 238 patients in the control arm).
The pattern of relapse was available for 419 patients; a large
proportion of patients in both arms relapsed in the central ner-
vous system, either as a single metastatic site (16% of relapsed
patients in the MVP arm and 16% of relapsed patients in the
control arm) or as part of more widespread disease (28% of
relapsed patients in the MVP arm and 31% of relapsed patients
in the control arm). Locoregional relapse was documented for
23% of patients in the MVP arm and for 22% of patients in the
control arm.
The primary outcome measure, overall survival, was ob-
served in 279 patients in the MVP arm and 289 patients in the
control arm. Comparison of the Kaplan–Meier curves for overall
survival gave a hazard ratio of 0.96 (95% confidence interval
[CI]  0.81 to 1.13; P  .589) (Fig. 2), which translates into
absolute increases in 2- and 5-year overall survival of 1% (95%
CI –3% to 5%) and 1% (95% CI –4% to 7%), respectively.
Median overall survival was 48 months for patients in the con-
trol arm and 55.2 months for patients in the MVP arm, but the
increase of 7.2 months (95% CI  –6.6 to 21.1 months) in
overall survival for the MVP arm derived by the Kaplan–Meier
curves estimate decreased to 2 months (95% CI  –5.5 to 11
months) when we calculated it using the hazard ratio and the
median survival in the control arm.
The secondary outcome measure, progression-free survival,
was observed in 310 patients in the MVP arm and 331 patients
in the control arm. Comparison of the Kaplan–Meier curves for
progression-free survival gave a hazard ratio of 0.89 (95% CI
0.76 to 1.03; P .128) in favor of the MVP arm (Fig. 3). This
hazard ratio represents absolute increases in 2- and 5-year pro-
gression-free survival of 4% (95% CI  –1% to 9%) and 4%
Table 1. Selected patient, disease, and treatment characteristics*
Characteristic
MVP group
(N  548)
Control group
(N  540)
Male, n (%) 472 (86) 465 (86)
Median age, y (range) 61 (33–76) 61 (37–76)
TNM pathologic stage, n (%)†
I 216 (39) 207 (38)
II 172 (31) 183 (34)
IIIA 160 (29) 150 (28)
T1 118 (22) 100 (19)
T2 345 (63) 360 (67)
T3 85 (16) 80 (15)
N0 257 (47) 254 (47)
N1 154 (28) 151 (28)
N2 137 (25) 135 (25)
Tumor histology, n (%)
Squamous cell carcinoma 278 (51) 262 (49)
Adenocarcinoma 196 (36) 206 (38)
Large-cell carcinoma 27 (5) 31 (6)
Bronchoalveolar carcinoma 23 (4) 20 (4)
Others‡ 24 (4) 21 (4)
Underwent pneumonectomy, n (%) 134 (24) 140 (26)
Complete lymph node dissection, n (%) 313 (57) 290 (54)
Underwent planned radiotherapy, n (%) 238 (43) 232 (43)
*MVPmitomycin C (8 mg/m2 on day 1), vindesine (3 mg/m2 on days 1 and
8), and cisplatin (100 mg/m2 on day 1) every 3 weeks for three cycles; TNM
tumor–node–metastasis.
†Reference (9).
‡Non–small-cell lung cancer without additional specifications.
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(95% CI –1% to 10%), respectively, for patients receiving the
MVP treatment. These Kaplan–Meier estimates of median pro-
gression-free survival times were 28.9 months for patients in the
control arm and 36.5 months for patients in the MVP arm (ab-
solute difference  7.6 months [95% CI  –1.5 to 16.6
months]; difference derived from hazard ratio and median pro-
gression-free survival in the control arm 3.6 months, 95% CI
 −0.8 to 9.1 months).
Figs. 4 and 5 depict the Kaplan–Meier curves for progres-
sion-free survival and overall survival, respectively, by disease
stage; no clear interaction between treatment and stage of dis-
ease emerged for either outcome measure. In the multivariable
analysis for selected baseline and treatment characteristics, stage
of disease and sex were statistically significantly associated with
overall survival (P<.001 for stage II or III versus stage I and
P  .034 for male versus female, respectively), whereas only
stage of disease was statistically significantly associated with
progression-free survival (P<.001 for stage II or III versus stage
I) (Table 2). We also performed a per-protocol analysis to com-
pare overall survival among patients who received all three
planned cycles of chemotherapy with that of patients who un-
derwent no adjuvant therapy and found no statistically signifi-
Fig. 2. Kaplan–Meier curves for overall survival
time from randomization by allocated treatment.
MVP mitomycin C (8 mg/m2 on day 1), vin-
desine (3 mg/m2 on days 1 and 8), and cisplatin
(100 mg/m2 on day 1) every 3 weeks for three
cycles.
Fig. 3. Kaplan–Meier curves for progression-
free survival time from randomization by allo-
cated treatment. MVP mitomycin C (8 mg/m2
on day 1), vindesine (3 mg/m2 on days 1 and 8),
and cisplatin (100 mg/m2 on day 1) every 3
weeks for three cycles.
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cant difference in overall survival between those two groups of
patients (HR  0.86, 95% CI  0.71 to 1.04).
Association Between Tumor Tissue Markers and Outcome
In NSCLC, the influence of other prognostic variables in
addition to tumor–node–metastasis stage and performance status
could explain the survival heterogeneity that has been observed
among patients with the same stage of the disease (17). Many
molecular and biologic features of NSCLC, including Ki67 and
p53 expression and K-ras mutation status, have been investi-
gated for their potential prognostic value (17). We analyzed 38%
of the primary tumors for levels of p53 and Ki67 expression.
Fifty percent of the tumor specimens expressed p53, and 62% of
the tumor specimens expressed Ki67 in more than 25% of tumor
cells examined (data not shown). We found no statistically sig-
nificant associations between disease stage or tumor histology
and tumor expression of p57 or Ki67, even when we considered
5%, 10%, and 25% cut points for positive cells (data not shown).
We also performed an analysis of the association between
K-ras mutation status and survival only among tumor specimens
that were histologically identified as adenocarcinoma or large-
cell carcinoma, because a preliminary analysis revealed that the
K-ras point mutation in exon 1 was present in only one (2%) of
the first 50 samples of squamous cell carcinoma we examined.
K-ras mutation status was examined by PCR amplification of
DNA extracted from tumor samples. We found point mutations
in exon 1 of the K-ras gene of 22% of the 117 tumor samples that
were successfully amplified by PCR (23 samples were not suc-
cessfully amplified). In a multivariable analysis that was ad-
justed for stage of disease, we found no association between any
of these three tumor tissue markers and overall survival or pro-
gression-free survival (Table 2).
DISCUSSION
The efficacy of adjuvant chemotherapy in completely re-
sected NSCLC is controversial, even though the results of more
Fig. 4. Kaplan–Meier curves for progression-
free survival from randomization by allocated
treatment and stage of disease. MVP  mito-
mycin C (8 mg/m2 on day 1), vindesine (3 mg/m2
on days 1 and 8), and cisplatin (100 mg/m2 on
day 1) every 3 weeks for three cycles; HR 
hazard ratio; CI  confidence interval.
Fig. 5. Kaplan–Meier curves for overall survival
time from randomization by allocated treatment
and stage of disease. MVP  mitomycin C
(8 mg/m2 on day 1), vindesine (3 mg/m2 on days
1 and 8), and cisplatin (100 mg/m2 on day 1)
every 3 weeks for three cycles; HR  hazard
ratio; CI  confidence interval.
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than 20 randomized clinical trials of chemotherapy alone versus
no chemotherapy are currently available [reviewed in (18)]. Re-
sults of the 1995 meta-analysis of NSCLC, which considered 17
trials of adjuvant chemotherapy versus best control, suggested
that only patients with completely resected NSCLC who re-
ceived cisplatin-based chemotherapy (eight trials) had a 5% im-
provement in 5-year survival rate compared with those treated
with surgery alone (7). However, these findings failed to influ-
ence clinical practice, not because the absolute gain was too
small, but because of the imprecision of the survival benefit
estimate, which ranged from a 1% detriment to a 10% benefit.
By contrast, clinical practice has been influenced by the results
of a meta-analysis of randomized clinical trials of adjuvant che-
motherapy in breast cancer involving approximately 75 000 pa-
tients, 31 000 recurrences, and 24 000 deaths that suggested a 6%
benefit in 10-year survival rate for women who received adju-
vant chemotherapy compared with those who did not (19).
Even more controversial is the efficacy of adjuvant radio-
therapy after radical surgery for NSCLC. For example, results of
a meta-analysis of trials involving patients with resected NSCLC
suggested that adjuvant radiotherapy was associated with a 7%
reduction in overall survival at 2 years; results of the subset
analyses suggested that this adverse effect was greatest for pa-
tients with stage I or II disease, whereas no clear evidence was
found for an adverse effect in patients with stage III disease (20).
Over the last decade, several randomized clinical trials of
platinum-based chemotherapy (with and without thoracic radio-
therapy) in completely resected stage I, II, and IIIA NSCLC
have been initiated and concluded. In one such trial, by the
Eastern Cooperative Oncology Group, patients with clinical
stage II or IIIA NSCLC received radiotherapy alone or concur-
rent chemotherapy and radiotherapy after complete resection
(21). Although overall toxicity was higher in the chemotherapy-
plus-radiotherapy group than in the radiotherapy-alone group,
there were no statistically significant differences in the efficacy
outcomes between the two groups (21). However, the results of
this study were limited by the lack of a surgery-alone arm and by
the modest sample size.
The ALPI trial was the first large, prospective adjuvant study
designed to detect reasonably small differences in survival that
were in the range of those detected by the NSCLC meta-analysis
(7). The ALPI trial was also the first large trial to successfully
enroll the number of patients very close to that originally
planned. This trial, however, failed to show any clinically sig-
nificant survival benefit for patients who received MVP treat-
ment after surgery. One possible reason for this result was the
low compliance with chemotherapy. Inadequate dose delivery is
often reported in most trials testing postoperative chemotherapy
[for review see (22)], with an average of 50% of patients receiv-
ing the full course of treatment. However, even when we per-
formed a per-protocol exploratory analysis that compared out-
comes among patients receiving all three planned cycles of
chemotherapy with those of patients undergoing no adjuvant
therapy, we found that MVP chemotherapy conferred only a
marginal, and still statistically nonsignificant, overall survival
advantage.
The health of patients who have undergone a major thoracic
surgical procedure is very often compromised by the procedure
itself, and these patients usually require a long time to fully
recover. Evidence supporting this observation is reflected in the
percentage of patients who never started adjuvant treatment (9%
in the ALPI trial and up to 24% of patients in previous studies)
(23). By contrast, compared with NSCLC patients, breast and
colon cancer patients undergo less debilitating surgeries and
receive less toxic adjuvant therapies, thereby allowing more ef-
fective delivery of those therapies.
When the ALPI trial was being planned, the choice of che-
motherapy regimen was greatly influenced by the positive data
reported from a trial comparing three chemotherapy regimens in
patients with advanced NSCLC (8) and by a report of the effi-
cacy of the MVP regimen in the neoadjuvant setting (24). Al-
though tumor shrinkage is one of the main aims of neoadjuvant
therapies, triplet combinations allow a higher objective response
rate than doublet combinations. In patients with stage IIIA
NSCLC, triplet combinations were used as induction regimens
in two small randomized phase III clinical studies (25,26) that
showed a clinically meaningful superiority of the combined ap-
proach over surgery alone.
Table 2. Multivariable Cox proportional hazards analysis for overall and progression-free survival*
Variable
Overall survival Progression-free survival
HR (95% CI) P value† HR (95% CI) P value†
Age, 5-y intervals 1.06 (1.00 to 1.12) .062 1.04 (0.99 to 1.10) .149
TNM pathologic stage‡
II versus I 2.01 (1.62 to 2.49) 1.88 (1.54 to 2.30)
III versus I 3.19 (2.59 to 3.93) <.001 2.94 (2.39 to 3.53) <.001
Tumor histology (squamous versus other) 0.87 (0.73 to 1.03) .112 0.84 (0.72 to 0.99) .037
Sex (male versus female) 1.33 (1.02 to 1.72) .034 1.19 (0.94 to 1.51) .150
Type of lymph node dissection (sampling versus complete) 0.88 (0.75 to 1.04) .135 0.86 (0.74 to 1.01) .068
MVP versus control 0.95 (0.81 to 1.12) .559 0.88 (0.76 to 1.03) .115
Tumor tissue markers§
p53 (n  387) 1.03 (0.98 to 1.08) .30 1.02 (0.97 to 1.06) .49
Ki67 (n  395) 1.42 (0.82 to 2.47) .63 1.04 (0.98 to 1.11) .16
K-ras gene mutation (n  108) 1.02 (0.95 to 1.08) .20 1.25 (0.73 to 2.14) .41
*The values in this table are adjusted for the other covariates reported in the table. HR hazard ratio; CI confidence interval; TNM tumor–node–metastasis;
MVP  mitomycin C (8 mg/m2 on day 1), vindesine (3 mg/m2 on days 1 and 8), and cisplatin (100 mg/m2 on day 1) every 3 weeks for three cycles.
†Wald test (two-sided) was used to estimate P values.
‡Reference (9).
§Data regarding tumor tissue markers were adjusted only by TNM pathologic stage and analyzed as continuous variables (Ki67 and p53) or as positive versus
negative (K-ras mutation).
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The amounts of grades 3 and 4 hematologic and non-
hematologic toxicities related to chemotherapy did not differ
quantitatively and qualitatively from those commonly observed
in advanced NSCLC; nonetheless, the marginal reduction in sur-
vival observed in the MVP arm in the first year after random-
ization could reflect a potential toxicity effect. This observation
is also indirectly confirmed by the lower percentage of patients
in the MVP arm than in the control arm that completed subse-
quent thoracic radiotherapy (65% versus 82%). However, the
treatment-related deaths occurring in the first year after random-
ization did not differ between the two treatment arms.
In the majority of the patients who have undergone complete
resection for NSCLC, death is cancer-related and follows sys-
temic recurrence. In our trial, this pattern was confirmed and,
more relevantly, in both arms, more than 40% of patients had
brain metastases as the first site of relapse. This issue not only
raises the question of how to prevent these brain metastases but
also suggests that prophylactic cranial irradiation should poten-
tially be investigated in these patients in future trials.
During the last decade, several new chemotherapeutic agents,
including gemcitabine, taxanes, and vinorelbine, became avail-
able and have been extensively investigated in advanced
NSCLC. When combined with cisplatin or carboplatin and com-
pared with older regimens, these new regimens resulted in a 13%
improvement in response rate and reduced toxicity but only in a
marginal increase in overall survival rate (27). Therefore, it is
unlikely that the use of these new regimens as adjuvant treatment
in early stages of NSCLC will greatly change the efficacy out-
comes.
In conclusion, the ALPI trial failed to confirm the effective-
ness of adjuvant MVP chemotherapy for patients with NSCLC.
Future trials of adjuvant therapy should be planned only when
the full results of all ongoing or completed randomized trials of
adjuvant therapy in NSCLC and of a new meta-analysis includ-
ing at least 4000 patients are available.
APPENDIX
Data management and statistical analysis: ALPI office Mario Negri
Institute, Milan, Italy: M. Flann, A. Cattaneo, I. Floriani, R. Fossati,
S. Marsoni, A. Tinazzi, V. Torri. EORTC office, Brussels, Belgium:
A. Kirkpatrick, A. Dehoorne.
The following investigators, listed according to accrual rate, contrib-
uted patients to the trial (all are located in Italy unless otherwise noted):
G. Liguori, G. Nittolo, M. Vasta, C. Curcio, Ascalesi Hospital, Naples;
P. Borasio, L. Dogliotti, G. V. Scagliotti, San Luigi Hospital, Or-
bassano, Turin; C. A. Angeletti, P. F. Conte, M. Laddaga, A. Rebec-
chini, S. Spagnesi, Santa Chiara Hospital, Pisa; T. Lewinski, Maria
Sklodowska-Curie Cancer Center, Warsaw, Poland; F. Salvati, F. De
Marinis, A. Altieri, F. Giordano, G. Puglisi, San Camillo-Forlanini
Hospital, Rome; A. Cipriani, A. Favaretto, M. Fiorentino, G. Giampa-
glia, L. Loreggian, R. Zuin, Civilian Hospital, Padova; J. Jassem, De-
partment of Oncology and Radiotherapy, Medical Academy, Gdansk,
Poland; R. Ukmar, A. Buffoni, C. Puricelli, G. Talmassons, A. Morelli,
Santa Maria Misericordia Civilian Hospital, Udine; A. Boidi Trotti,
S. Bretti, G. Maggi, A. Mussa, G. L. Sannazzari, S. Baldi, U. Ricardi,
E. Ruffini, San Giovanni Hospital, Turin; G. Bruni, C. Gridelli, Na-
tional Institute of Cancer, Naples; F. Checcaglini, Santa Maria Hospital,
Terni; P. Latini, E. Maranzano, T. Todisco, M. Tonato, Monteluce
General Hospital, Perugia; A. Santo Antonio, A. Terzi, Verona Hospi-
tal, Verona; G. Pavia, A. Sartirana, Civilian Hospital, Rho, Milan;
D. Ottoni, Civilian Hospital, Brescia; M. Fontanili, C. Sturani, “C.
Poma” Hospital, Mantova; L. M. Aiello, S. Barbera, Santa Mariano
Hospital, Cosenza; F. Baracco, A. Cinquegrana, R. Felletti, T. Scolaro,
J. Serrano, Santa Martino Hospital, Genoa; U. Felci, Riuniti Hospital,
Bergamo; P. Manente, Civilian Hospital, Castelfranco Veneto, Treviso;
P. Drings, Thorax Klinik Rohrbach, Heidelberg, Germany; P. Zannini,
E. Villa, San Raffaele Hospital, Milan; N. Bordone, M. Tordiglione,
M. Bandera, M. Fioretti, Circolo Hospital and Filippo del Ponte Hos-
pital, Varese; G. Roviaro, San Giuseppe Hospital, Milan; A. R. Bianco,
G. Ferrante, A. Rossi, A. Sodano, Federico II General Hospital, Naples;
C. Boni, L. Covacev, V. Lodini, Santa Maria Nuova Hospital, Reggio
Emilia; P. Espana, Oncologia Medica, Clinica Puerta de Hierro,
Madrid, Spain; P. A. Belloni, E. Soresi, U. Borghini, G. Cimino,
M. Leoni, M. Ravini, Riguarda Ca’ Grande Hospital, Milan; G. Lu-
porini, G. Todeschini, San Carlo Hospital, Milan; N. Campioni,
F. Cognetti, F. Facciolo, Regina Elena Institute, Rome; V. Clini, E. Tisi,
Santa Gerardo Tintori Hospital, Monza, Milan; G. Bolzicco, M. Guli-
sano, R. Negrin, M. Vidali, Civilian Hospital, Vicenza; M. Musi,
F. Ozzello, L. Sblendorio, Regional Hospital, Aosta; G. Buccheri,
D. Ferrigno, G. Marchetti, M. Quaranta, Santa Croce e Carle Hospital,
Cuneo; F. Virginio, P. Elena, Luigi Sacco Hospital, Milan; G. Arcan-
geli, G. Baiano, F. Cardillo, M. D’Aprile, Santa Maria Goretti Hospital,
Latina; G. Bragherio, A. De Stefano, V. Lanzetti, Legnano Hospital,
Magenta, Milan; L. Armaroli, Santa Maria Nuova Hospital, Regio
Emilia; G. Barbera, C. Lanfranco, M. Morelli, P. Rotta, F. Testore,
Civilian Hospital, Asti; A. Bordin, G. Degli Angeli, Provincial General
Hospital, Belluno; G. Biasco, University of Bologna, Seragnoli Institute
of Hematology and Oncology, Bologna; A. Desogus, Businco Oncol-
ogy Hospital, Cagliari, Sardegna; L. Gandola, Maggiore Hospital,
Crema, Cremona; L. Landa, R. Mattioli, S. Croce General Hospital,
Fano; F. Di Costanzo, S. Gasperoni, A. Lopes Pegna, Careggi Hospital,
Florence Careggi; G. W. P. Kramer, Arnhem, The Netherlands; P. Foa,
A. Mantovani, S. Paolo Hospital, Milan; P. Astorre, R. Maritati,
M. Nardi, Celio Military General Hospital, Rome; F. Bassi, T. Tom-
maseo-Ponzet, G. Di Falco, G. Marazzato, G. Nicolai, G. Santelli, Ca’
Fondello Hospital, Treviso; F. Gozzelino, G. Moro, Hospital for Inva-
lids, Biella; G. Ghiotti, B. Rho, Salvini Hospital, Garbagnate, Milan;
M. Marcellini, Civilian Hospital, Senigaglia, Ancona; F. Bassan, Bol-
drini Regional General Hospital, Tiene, Vicenza; G. Fornari, Valdese
Evangelist Hospital, Torino; F. Artioli, Ramazzini Hospital, Carpi,
Modena; C. Zambianchi, L. Amaducci, Hospital for Invalids, Faenza,
Ravenna; G. Airoldi, Santa Giovanni Battista Hospital, Gattinara, Ver-
celli; G. Cruciani, Umberto I Hospital, Lugo di Romagna, Ravenna;
S. Di Prima, Civilian Hospital, Moncalieri, Torino; M. Spatafora Mario,
Cervello Hospital, Palermo; G. Cacciani, Parma Hospital, Parma;
C. Ricci, E. Cortesi, A. Dagianti, V. Donato, E. A. Rendina, F. Romeo,
F. Venuta, Umberto I General Hospital, University La Sapienza, Rome;
E. Longhini, Sesto S. Giovanni Hospital, Sesto S. Giovanni, Milan;
P. Fasullo, Santa Luca Hospital, Vallo della Lucania, Salerno; S. Gans,
Harderwijk, The Netherlands; H. Karnicka, Department of Oncology,
University Hospital, Gdansk, Poland; S. Barni, Piazzave Hospital,
Treviglio.
Biological Prognostic Factors Subcommittee: A. Marchetti, Depart-
ment of Pathology, University of Chieti, Chieti, Italy; Eugenio Leo-
nardo, Paolo De Giuli, Susanna Cappia, Department of Pathology,
Santa Luigi Hospital, Orbassano (Torino), Italy.
Data Monitoring Committee: G. J. McVie, Cancer Intelligence, Lon-
don, United Kingdom; U. Pastorino, National Cancer Institute, Milan,
Italy; P. van Houtte, Institute Jules Bordet, Brussels; Belgium; M. G.
Valsecchi, University of Milano-Bicocca, Dipartimento di Medicina
Clinica, Prevenzione e Biotecnologie Sanitarie, Milan, Italy.
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